(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
21 October 2021 (21.10.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/209627 A1

(51) International Patent Classification:
A61K 35/17 (2015.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/EP2021/059989

(22) International Filing Date:
16 April 2021 (16.04.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2005599.2 17 April 2020 (17.04.2020) GB

(71) Applicant: **CANCER RESEARCH TECHNOLOGY LIMITED** [GB/GB]; 2 Redman Place, London Greater London E20 1JQ (GB).

(72) Inventors: **QUEZADA, Sergio**; c/o Cancer Research Technology Limited, 2 Redman Place, London Greater London E20 1JQ (GB). **PEGGS, Karl**; c/o Cancer Research Technology Limited, 2 Redman Place, London Greater London E20 1JQ (GB). **SWANTON, Charles**; c/o Cancer Research Technology Limited, 2 Redman Place, London Greater London E20 1JQ (GB). **GHORANI, Ehsan**; c/o Cancer Research Technology Limited, 2 Redman Place, London Greater London E20 1JQ (GB). **READING, James**; c/o Cancer Research Technology Limited, 2 Redman Place, London Greater London E20 1JQ (GB). **GALVEZ-CANCINO, Felipe**; c/o Cancer Research Technology Limited, 2 Redman Place, London Greater London E20 1JQ (GB). **KARAGIANNI, Despoina**; c/o Cancer Research Technology Limited, 2 Redman Place, London Greater London E20 1JQ (GB).

(74) Agent: **MEWBURN ELLIS LLP**; Aurora Building, Counterslip, Bristol Bristol BS1 6BX (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*

WO 2021/209627 A1

(54) **Title:** MODULATION OF T CELL CYTOTOXICITY AND RELATED THERAPY

(57) **Abstract:** The present invention provides an engineered T cell for use in a method of treatment of a proliferative disorder, wherein the engineered T cell has modulated expression of one or more genes selected from *SIT1, SAMSN1, SIRPG, CD7, CD82, FCRL3, IL1RAP, FURIN, STOM, AXL, E2F1, C5ORF30, CLDND1, COTL1, DUSP4, EPHA1, FABP5, GFI1, ITM2A, PARK7, PECAM1, PHLDA1, RAB27A, RBPJ, RGS1, RGS2, RNASEH2A, SUV39H1*, and *TNIP3*. Further provided are activity modulators of one or more proteins encoded by genes selected from *SIT1, SAMSN1, SIRPG, CD7, CD82, FCRL3, IL1RAP, FURIN, STOM, AXL, E2F1, C5ORF30, CLDND1, COTL1, DUSP4, EPHA1, FABP5, GFI1, ITM2A, PARK7, PECAM1, PHLDA1, RAB27A, RBPJ, RGS1, RGS2, RNASEH2A, SUV39H1*, and *TNIP3* for use in a method of enhancing immunotherapy in a subject having a proliferative disorder. Also provided are related methods of treatment employing the engineered T cell and/or inhibitor.